Comparative Pharmacology
Head-to-head clinical analysis: NAPROXEN SODIUM versus TOLECTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NAPROXEN SODIUM versus TOLECTIN.
NAPROXEN SODIUM vs TOLECTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis.
220-550 mg orally twice daily; maximum 1375 mg/day.
400-600 mg orally three times daily; maximum 1.8 g/day.
None Documented
None Documented
12–17 hours (terminal); allows twice-daily dosing; prolonged in elderly and renal impairment
Terminal half-life approximately 5-6 hours; clinical context: dosing every 6-8 hours required due to relatively short half-life; steady-state achieved within 24-30 hours.
Renal: 95% (as unchanged drug, conjugated naproxen, and 6-O-desmethyl naproxen); Fecal: <5%
Renal (90-95% as unchanged drug and metabolites, primarily glucuronide conjugates); biliary/fecal (minor, <5%).
Category D/X
Category C
NSAID
NSAID